Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily rifampicin for four months vs daily rifampicin + isoniazid for three months in latent tuberculosis infection among migrants
2021-001438-20Phase 4Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in latent tuberculosis infection (LTBI) comparing 4-month daily rifampicin (4R) with 3-month daily rifampicin + isoniazid (3RH) (2 arms). Primary endpoint: Regimen completion rate. Started Aug 2021; status: completed.
02
Drugs
rifampicinisoniazid
03
Conditions
latent tuberculosis infection (LTBI)
Beyond the preview
Go deeper on 2021-001438-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001438-20.